Inspira Technologies receives US patent for respiratory support system

RA’ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), a medical device company with a market capitalization of $32.28 million, has received U.S. patent approval for its low flow rates extracorporeal oxygenation system and methods, the company announced Friday. The stock has shown strong momentum, gaining over 43% in the past six months, according to InvestingPro data.

The patent, which provides protection until at least 2043, covers the core technology of the company’s ART500 device. The innovation includes 16 claims found to be novel and is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency.

According to the company, the technology targets patients requiring respiratory support who may not need traditional high-flow ECMO systems, potentially expanding the market for Inspira’s technology.

"This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of $20 billion," said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. "We are creating a new therapeutic category for conscious, spontaneously breathing patients." Analysts appear optimistic about the company’s prospects, with InvestingPro data showing a price target of $3.00, suggesting significant potential upside from current levels.

The company stated it is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage.

Inspira Technologies’ FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. The company is also developing HYLA, described as a proprietary blood sensor platform offering continuous, non-invasive monitoring.

The information in this article is based on a company press release statement.

In other recent news, Inspira Technologies OXY B.H.N. Ltd. has announced several significant developments. The company has received a $27 million binding purchase order from a national health ministry in Africa for its FDA-cleared ART100 systems. This order will lead to an immediate deployment program across the nation, with full payment expected by 2025. Additionally, Inspira Technologies has secured another $22.5 million purchase order for the ART100 system from a private entity outside the United States, with payment also scheduled for 2025.

Inspira Technologies is also in discussions with a foreign government to potentially integrate the ART100 system into its national emergency infrastructure. The company has further engaged a specialized consulting firm to support its strategic expansion and enhance enterprise value. Lastly, Inspira Technologies has filed a routine shelf registration statement renewal with the U.S. Securities and Exchange Commission, replacing the previous one set to expire in 2025. These recent developments highlight the company’s ongoing efforts to expand its market presence and strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.